APTA.L - Aptamer Group plc
| Previous Close | 9.00 |
| Open | 8.02 |
| Bid | 8.00 x N/A |
| Ask | 13.00 x N/A |
| Day's Range | 8.02 - 9.90 |
| 52 Week Range | 8.00 - 100.00 |
| Volume | |
| Avg. Volume | 13,541 |
| Market Cap | 6.218M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.05 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 180.00 |
Simply Wall St.Aptamer Group First Half 2023 Earnings: UK£0.038 loss per share (vs UK£0.018 loss in 1H 2022)
Aptamer Group ( LON:APTA ) First Half 2023 Results Key Financial Results Revenue: UK£1.02m (down 26% from 1H 2022). Net...
News DirectAptamer Group "anticipating higher revenues" in its second half
Aptamer Group PLC (AIM:APTA) CEO Dr Arron Tolley speaks to Proactive's Thomas Warner following the release of the company's interim results.
- Simply Wall St.
Aptamer Group (LON:APTA) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
GlobeNewswireAptamer Group Appointment of Interim Chief Commercial Officer
10 January 2023 Aptamer Group plc(“Aptamer”, the “Company” or the “Group”) Appointment of Interim Chief Commercial Officer Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the appointment of Derek Smith as Interim Chief Commercial Officer, effective as of 1st January 2023. Derek joined the Company in 2018 as Director of Global Sales and has since become a vital part of the Aptamer team, overseeing the devel
The GuardianAptamer: the York biotech working on precision cancer treatments
UK firm links with up global drug firms to make synthetic antibodies capable of binding to targets such as tumour cells